MX2016009306A - Reequilibrado inmunologico epicutaneo. - Google Patents

Reequilibrado inmunologico epicutaneo.

Info

Publication number
MX2016009306A
MX2016009306A MX2016009306A MX2016009306A MX2016009306A MX 2016009306 A MX2016009306 A MX 2016009306A MX 2016009306 A MX2016009306 A MX 2016009306A MX 2016009306 A MX2016009306 A MX 2016009306A MX 2016009306 A MX2016009306 A MX 2016009306A
Authority
MX
Mexico
Prior art keywords
subject
epicutaneous
improve
context
immunorebalancing
Prior art date
Application number
MX2016009306A
Other languages
English (en)
Inventor
Mondoulet Lucie
DIOSZEGHY Vincent
Henri Benhamou Pierre
Dupont Christophe
Original Assignee
Dbv Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dbv Tech filed Critical Dbv Tech
Publication of MX2016009306A publication Critical patent/MX2016009306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Abstract

La presente invención se refiere a composiciones y métodos para mejorar una afección en un sujeto mediante reequilibrado epicutáneo. La invención muestra que se pueden inducir células T reguladoras concretas y mantener en un sujeto mediante tratamiento epicutáneo, causando con ello una mejora sustancial de una afección en un sujeto. La invención se puede usar en un contexto preventivo para mejorar el equilibrio inmunológico de un sujeto y evitar la aparición o el desarrollo de enfermedades, así como en un contexto terapéutico para mejorar la recuperación de un sujeto. La invención es particularmente adecuada para prevenir o tratar una enfermedad proliferativa o autoinmune. La invención se puede usar en cualquier sujeto mamífero, preferentemente en sujetos humanos, incluyendo niños y adultos.
MX2016009306A 2014-01-17 2015-01-14 Reequilibrado inmunologico epicutaneo. MX2016009306A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461928716P 2014-01-17 2014-01-17
PCT/EP2015/050594 WO2015107081A1 (en) 2014-01-17 2015-01-14 Epicutaneous immunorebalancing

Publications (1)

Publication Number Publication Date
MX2016009306A true MX2016009306A (es) 2017-04-10

Family

ID=52347336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009306A MX2016009306A (es) 2014-01-17 2015-01-14 Reequilibrado inmunologico epicutaneo.

Country Status (12)

Country Link
US (1) US20160331834A1 (es)
EP (1) EP3094335A1 (es)
JP (1) JP2017505766A (es)
KR (1) KR20160107328A (es)
CN (1) CN106163555A (es)
AU (1) AU2015206046A1 (es)
BR (1) BR112016016525A2 (es)
CA (1) CA2936259A1 (es)
EA (1) EA201691443A1 (es)
IL (1) IL246499A0 (es)
MX (1) MX2016009306A (es)
WO (1) WO2015107081A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
IL272033B2 (en) 2017-07-18 2023-09-01 Before Brands Inc Methods for the preparation of mixed allergen preparations
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CA3127337A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
US11622943B2 (en) 2019-05-10 2023-04-11 Chamkurkishtiah Panduranga Rao System and method for allergen-specific epicutaneous immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005284793B2 (en) * 2004-09-15 2011-07-07 The Trustees Of The University Of Pennsylvania Methods for the isolation and expansion of cord blood derived T regulatory cells
WO2009126877A2 (en) * 2008-04-11 2009-10-15 University Of Southern California Methods and compositions for accelerating the generation of regulatory tcells ex vivo
JP2013059295A (ja) * 2011-09-14 2013-04-04 Nagoya City Univ ｓｉＲＮＡ、抗原提示細胞、制御性Ｔ細胞及び治療薬
EP2626082A1 (en) * 2012-02-13 2013-08-14 DBV Technologies Method of preventing allergies

Also Published As

Publication number Publication date
EA201691443A1 (ru) 2016-12-30
IL246499A0 (en) 2016-08-31
JP2017505766A (ja) 2017-02-23
CN106163555A (zh) 2016-11-23
WO2015107081A1 (en) 2015-07-23
US20160331834A1 (en) 2016-11-17
AU2015206046A1 (en) 2016-07-21
CA2936259A1 (en) 2015-07-23
BR112016016525A2 (pt) 2017-08-08
KR20160107328A (ko) 2016-09-13
EP3094335A1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
TW201613636A (en) Methods of treating Alzheimer's Disease
PH12018501443A1 (en) Methods of administering hepcidin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
EA201691567A1 (ru) Способы лечения легких травм головного мозга
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
MX2019000677A (es) Células miméticas de células b.
PH12019501358A1 (en) Methods of administering hepcidin
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
EA202092554A1 (ru) Композиции для лечения кожных заболеваний
WO2017075190A3 (en) Generation of adult-like heart muscle from human pluripotent stem cells
BR112017012912A2 (pt) prevenção de insuficiência cardíaca progressiva
RU2014116784A (ru) Способ лечения заболеваний пародонта
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
MX2012014799A (es) Composición medicinal, método de preparación y uso de la misma.
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
UA97257U (uk) Спосіб профілактики та лікування серцево-судинних захворювань